Form 13-F position report

PLUS THERAPEUTICS INC

Reported by GEODE CAPITAL MANAGEMENT LLC

PSTV CUSIP 72941H509 Manager CIK 0001214717

Reported 54,274 shares, up 7,626 (16.3%) from the prior quarter.

Reported value 15.6%; share count 16.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2024
Shares 54,274 Quarter-end amount reported
Reported value $79,239 Fair value at quarter end
Consecutive quarters held 14 Through Q3 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 271000
2022-03-31 258000
2022-06-30 139000
2022-09-30 115000
2022-12-31 81000
2023-03-31 73993
2023-06-30 34354
2023-06-30 0
2023-09-30 35567
2023-12-31 47511
2024-03-31 52819
2024-06-30 68572
2024-09-30 79239
2024-12-31 66872
2025-03-31 54205
2025-06-30 17798
2025-09-30 556018
2025-12-31 719028
2026-03-31 327979
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for PLUS THERAPEUTICS INC held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -2,016,314 (-100.0%) 0 $0 2026-08-12
Q1 2026 Added 2,016,314 +613,520 (43.7%) < 0.01% $327,979 2026-05-15
Q4 2025 Added 1,402,794 +589,544 (72.5%) < 0.01% $719,028 2026-02-09
Q3 2025 Added 813,250 +762,074 (1489.1%) < 0.01% $556,018 2025-11-12
Q2 2025 Reduced 51,176 -5,877 (-10.3%) < 0.01% $17,798 2025-08-08
Q1 2025 Reduced 57,053 -1,097 (-1.9%) < 0.01% $54,205 2025-05-13
Q4 2024 Added 58,150 +3,876 (7.1%) < 0.01% $66,872 2025-02-12
Q3 2024 Added 54,274 +7,626 (16.3%) < 0.01% $79,239 2024-11-12
Q2 2024 Added 46,648 +17,385 (59.4%) < 0.01% $68,572 2024-08-09
Q1 2024 Added 29,263 +2,720 (10.2%) < 0.01% $52,819 2024-05-13
Q4 2023 Unchanged 26,543 0 (0.0%) < 0.01% $47,511 2024-02-13
Q3 2023 Added 26,543 +9,536 (56.1%) < 0.01% $35,567 2023-11-13
Q2 2023 Reduced 0 -255,148 (-100.0%) 0 $0 2023-08-11
Q2 2023 New 17,007 +17,007 (0.0%) < 0.01% $34,354 2023-08-11
Q1 2023 Reduced 255,148 -2,904 (-1.1%) < 0.01% $73,993 2023-05-15
Q4 2022 Reduced 258,052 -385 (-0.1%) < 0.01% $81,000 2023-02-13
Q3 2022 Unchanged 258,437 0 (0.0%) < 0.01% $115,000 2022-11-14
Q2 2022 Unchanged 258,437 0 (0.0%) < 0.01% $139,000 2022-08-12
Q1 2022 Unchanged 258,437 0 (0.0%) < 0.01% $258,000 2022-05-13
Q4 2021 Unchanged 258,437 0 (0.0%) < 0.01% $271,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

12 managers reported PLUS THERAPEUTICS INC for Q3 2024.

Managers reporting PLUS THERAPEUTICS INC in Q3 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
AIGH Capital Management LLC Reduced 560,905 -7,776 0.23% $818,921 2 qtrs
GEODE CAPITAL MANAGEMENT LLC This report Added 54,274 +7,626 < 0.01% $79,239 6 qtrs
VANGUARD GROUP INC Unchanged 32,541 0 < 0.01% $47,510 6 qtrs
Ashton Thomas Private Wealth LLC Added 12,913 +12,098 < 0.01% $18,853 2 qtrs
BlackRock Inc New 6,960 +6,960 < 0.01% $10,162 1 qtr
Tower Research Capital LLC TRC Reduced 3,709 -477 < 0.01% $5,415 6 qtrs
ADVISOR GROUP HOLDINGS INC Unchanged 133 0 < 0.01% $194 6 qtrs
JPMorgan Chase & Co Unchanged 100 0 < 0.01% $146 5 qtrs
Bank of America Corporation Added 48 +1 < 0.01% $70 2 qtrs
UBS Group AG Reduced 0 -3,199 0 $0 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2024
Filed
November 12, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
54,274
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.